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A B S T R A C T
The present study aimed at the phytochemical and pharmacological investigation of Sideritis montana L.
(Lamiaceae). Two new abietane diterpenes [sideritins A (1) and B (2)] were isolated from the methanol extract
of the plant. Six known compounds [pomiferin E (3), 9α,13α-epi-dioxyabiet-8(14)-en-18-ol (4), paulownin (5),
6-methoxysakuranetin (6), 3-oxo-α-ionol (7) and 4-allyl-2,6-dimethoxyphenol glucoside (8)] were also obtained
from the plant. The structures were determined by means of HREIMS and NMR experiments. The anti-
proliferative eﬀect of the isolated compounds was investigated on human cancer cell lines (HeLa, SiHa and
C33A) at 10 and 30 μM concentrations, using the MTT assay. The results demonstrated that pomiferin E (3) and
6-methoxysakuranetin (6) displayed considerable activity [inhibition (%) ± SEM: 46.93 ± 2.35 on HeLa
(pomiferin E), and 51.52 ± 2.45 on C33A (6-methoxysakuranetin)] at 30 μM concentration.
1. Introduction
The genus Sideritis (Lamiaceae family) includes more than 150
species, which are distributed widely in the Mediterranean area [1].
These plants are traditionally used as remedies for several disorders,
such as anti-ulcerative, vulnerary, anticonvulsant, and analgesic agents.
Infusions and decoctions prepared from Sideritis species are consumed
frequently, since the extracts of plants possess diﬀerent pharmacolo-
gical activities, including antioxidant, anti-inﬂammatory, anti-
microbial, spasmolytic and carminative eﬀects [2].
Previously iridoid glycosides (ajugol, ajugoside and melittoside), a
ﬂavonoid (diosmetin), and a phenylethanoid glycoside (verbascoside)
have been isolated from Sideritis montana L. The volatile oil of the plant
contains considerable amounts of sesquiterpenes, such as germacrene D
and bicyclogermacrene. The triterpenoid constituents (ergosterol, stig-
masterol and β-sitosterol) of S. montana seeds have also been identiﬁed
by HPLC. Up to now, only one diterpenoid, siderol was described from
the plant, but its detailed spectroscopic analysis was not reported [3].
The investigation of secondary metabolites of S. montana subsp. mon-
tana resulted in the identiﬁcation of ﬂavonoids (isoscutellarein deri-
vatives), chlorogenic acid, methylarbutin and iridoids (e.g. harpagide,
melittoside). The essential oil of the plant was mainly characterized by
sesquiterpene hydrocarbons (germacrene D and bicyclogermacrene)
[4].
Recently, the eﬀect of hydroalcoholic extracts prepared from S.
euboea and S. scardica (named as Greek mountain tea) was tested in
Alzheimer's β-amyloidosis mouse models and investigated their activ-
ities on memory and learning processes. It was observed that daily oral
treatment of the extracts enhanced cognition in aged, non-transgenic as
well as in APP-transgenic mice. These results support the traditional use
of Sideritis species in the prevention of age-related problems (e.g. de-
menting disorders like Alzheimer's disease) in elderly individuals [5].
The essential oil of S. montana subsp. montana showed moderate cyto-
toxicity on A375, MDA-MB 231 and HCT116 cell lines, and weak an-
tioxidant activity [4].
The aim of the present study was to perform a preparative phyto-
chemical work with S. montana, and to investigate the antiproliferative
properties of the isolated compounds.
2. Experimental
2.1. General
Vacuum liquid chromatography (VLC) was carried out on silica gel
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(15 μm, Merck); LiChroprep RP-18 (40–63 μm, Merck) stationary phase
was used for reversed-phase VLC; column chromatography (CC) was
performed on polyamide (MP Biomedicals). Preparative thin-layer
chromatography (preparative TLC) was performed on silica gel 60 F254
plates (Merck) as well on reversed-phase silica gel 60 RP-18 F254 plates
(Merck). Rotation planar chromatography (RPC) was carried out on
silica gel 60 GF254 with a Chromatotron instrument (Model 8924,
Harrison Research). Centrifugal partition chromatography (CPC) was
performed on Armen SCPC apparatus (Armen Instrument Sas, Saint-
Avé, France) equipped with a gradient pump, a 10 mL sample loop, an
ASC/DSC valve, a 250 mL column, a UV detector, and an automatic
fraction collector. The system was controlled by Armen Glider software.
NMR spectra were recorded in CDCl3 and DMSO-d6 on a Bruker
Avance DRX 500 spectrometer at 500 MHz (1H) and 125 MHz (13C).
The signals of the deuterated solvents were taken as references. The
chemical shift values (δ) were given in ppm and coupling constants (J)
are in Hz. Two-dimensional (2D) experiments were performed with
standard Bruker software. In the COSY, HSQC and HMBC experiments,
gradient-enhanced versions were used. The high resolution MS spectra
were acquired on a Thermo Scientiﬁc Q-Exactive Plus Orbitrap mass
spectrometer equipped with ESI ion source in positive ionization mode.
The resolution was over 1 ppm. The data were acquired and processed
with MassLynx software. All solvents used for CC were of at least
analytical grade (VWR Ltd., Szeged, Hungary).
2.2. Plant material
Sideritis montana was collected during the ﬂowering period in July
2013, near Öskü (Hungary). Botanical identiﬁcation of the plant ma-
terial was performed by one of the authors, Dr. Gyula Pinke
(Department of Botany, University of West Hungary,
Mosonmagyaróvár, Hungary) and a voucher specimen (No 822) has
been deposited at the Herbarium of the Department of Pharmacognosy,
University of Szeged, Szeged, Hungary.
2.3. Extraction and isolation
The air-dried whole plant of S. montana (2.8 kg) was percolated
with MeOH (60 L) at room temperature. The crude methanol extract
was concentrated under reduced pressure (637.4 g) and subjected to
solvent–solvent partitioning with n-hexane, CHCl3, and EtOAc.
5 × 1.5 L solvent was used for each partitioning.
The concentrated n-hexane soluble fraction (S1) (49.5 g) was se-
parated by polyamide open column chromatography with gradient
system of MeOH–H2O [2:3, 3:2, 4:1, 1:0 (3, 2.5, 3.5 and 2 L, respec-
tively), each eluent was collected as a fraction]. The fraction obtained
from the polyamide column with MeOH–H2O 3:2 (S1/2) (2.43 g) was
subjected to vacuum liquid chromatography on silica gel (VLC,
Kieselgel GF254, Merck) with a gradient system of
cyclohexane–EtOAc–MeOH [from 9:1:0 to 5:5:1 (200 mL/eluent), and
ﬁnally with MeOH (150 mL); volume of collected fractions were 20 mL]
to yield the major fractions S1/2/1–6. The fractions were combined
according to their TLC patterns, using cyclohexane–EtOAc–MeOH
(20:10:1) as solvent system (detection at 254 and 366 nm, and at
daylight after spraying with vanillin-sulfuric acid reagent and heating
at 120 °C for 5 min).
Fraction S1/2/2 (48.7 mg) was separated by reversed-phase VLC,
which was eluted with a gradient system of MeOH–H2O [from 2:3 to 9:1
(100 mL/eluent), and ﬁnally MeOH (100 mL); volume of collected
fractions was 10 mL] to yield six subfractions. Compound 3 (4.2 mg)
was obtained from subfraction S1/2/2/5 (13.6 mg) by preparative TLC
on silica gel 60 F254 plates using toluene-acetone (8:2) as solvent
system.
Fraction S1/2/3 (38.0 mg) was also puriﬁed by reversed-phase VLC,
a gradient system of MeOH–H2O [from 3:7 to 9:1 (100 mL/eluent), and
ﬁnally MeOH (100 mL)] was used as eluent; (volume of collected
fractions was 10 mL) to aﬀord ﬁve subfractions. From subfraction S1/
2/3/3 (14.3 mg) compound 5 (4.7 mg) was puriﬁed by preparative TLC
on silica gel 60 F254 plates using toluene–acetone (8:2) as solvent
system.
Reversed-phase VLC was used for the separation of fraction S1/2/4
(117.1 mg). The fraction was eluted by a gradient system of MeOH–H2O
[from 3:7 to 9:1 (120 mL/eluent), and ﬁnally MeOH (150 mL), volume
of collected fractions was 10 mL] to aﬀord nine subfractions. By the use
of preparative TLC on silica gel 60 F254 plates using toluene–acetone
(8:2) as solvent system compound 1 (5.7 mg) and compound 4 (3.1 mg)
were isolated from subfractions S1/2/4/3 (11.1 mg) and S1/2/4/6
(9.3 mg), respectively.
Fraction S1/2/5 (148.3 mg) was also chromatographed by reversed-
phase VLC, which was eluted with a gradient system of MeOH–H2O
[from 3:7 to 9:1 (150 mL/eluent), and ﬁnally MeOH (100 mL); volume
of collected fractions was 10 mL] to aﬀord ﬁve combined fractions.
Fraction S1/2/5/1 (24.1 mg) was puriﬁed by the use of preparative TLC
on silica gel 60 F254 plates using toluene–acetone (8:2) as solvent
system to yield compound 2 (7.2 mg) and compound 6 (4.6 mg).
The CHCl3-soluble fraction (S2) (35.5 g) was chromatographed on a
polyamide column with gradient system of MeOH–H2O [1:4, 2:3, 3:2,
4:1, 1:0 (2.5, 2.5, 3, 3.5, and 2 L, respectively)] to give nine combined
fractions (S2/1-9). Fraction S2/1 (5.73 g) was further chromatographed
by VLC on silica gel with a gradient system of CHCl3–MeOH [from
100:1 to 1:1 (500 mL/eluent), and ﬁnally with MeOH (400 mL); volume
of collected fractions were 50 mL] to yield twelve major fractions (S2/
1/1-12). The fractions were concentrated and monitored by TLC using
CHCl3–MeOH (95:5 and 9:1) and EtOAc–EtOH–H2O (25:4:3) as solvent
system. Subfraction S2/1/4 (225.4 mg) was separated by RPC on silica
gel 60 GF254 with the use of CH2Cl2–MeOH gradient elution [from 99:1
to 7:3 (150 mL/eluent), and ﬁnally with MeOH (100 mL); volume of
collected fractions were 20 mL] to yield seven subfractions. Compound
7 (3.9 mg) was puriﬁed from subfraction S2/1/4/4 (30.2 mg) using
preparative TLC on reversed-phase silica gel 60 RP-18 F254 plates with
MeOH–H2O (7:3) as solvent system.
Fraction S2/1/9 (960.3 mg) was chromatographed with CPC, using
a two-phase solvent system consisting of CHCl3–MeOH–H2O 10:3:7
(1000 rpm, 10 mL/min ﬂow rate, 90 min) in the ascending mode. After
combination eight subfractions were obtained. From subfraction S2/1/
9/4 (24.5 mg) compound 8 (4.7 mg) was isolated by the use of pre-
parative TLC on reversed-phase silica gel 60 RP-18 F254 plates with
MeOH–H2O (7:3) as eluent.
2.3.1. Sideritin A (1)
Yellow amorphous solid; [α]D26 + 47 (c 0.1, MeOH); 1H and 13C
NMR data see Table 1; HRESIMS m/z 285.2217 [M–H2O + H]+ (calcd
for C20H29O, 285.2213).
2.3.2. Sideritin B (2)
Yellow amorphous solid; [α]D26− 7 (c 0.2, MeOH); 1H and 13C
NMR data see Table 1; HRESIMS m/z 359.2198 [M + Na]+ (calcd for
C20H32O4Na, 359.2193) providing the molecular formula, C20H32O4.
2.3.3. Pomiferin E (3)
13C NMR (CDCl3, 125 MHz) δ 199.3 (C]O, C-7), 152.7 (C, C-9),
147.1 (C, C-13), 132.7 (CH, C-12), 130.5 (C, C-8), 125.1 (CH, C-14),
123.4 (CH, C-11), 65.0 (CH, C-2), 50.5 (CH2, C-3), 48.7 (C, C-4), 46.9
(CH2, C-1), 39.4 (C, C-10), 36.0 (CH2, C-6), 34.8 (CH, C-15), 33.6 (CH3,
C-19), 32.6 (CH, C-5), 23.8 (CH3, C-16), 23.7 (CH3, C-17), 24.4 (CH3, C-
20), 22.0 (CH3, C-18).
2.4. Bioassay
Antiproliferative eﬀect of the isolated compounds (1–7) were
measured in vitro on human cervical cancer cell lines (HeLa, SiHa, and
C33A) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
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bromide (MTT) colorimetric assay. These cell lines were purchased
from the European Collection of Cell Cultures (Salisbury, UK) and
maintained in minimal essential medium supplemented with 10% fetal
bovine serum, 1% nonessential amino acids, and an antibiotic-anti-
mycotic mixture, in a humidiﬁed atmosphere of 5% CO2 at 37 °C. All of
the chemicals, if otherwise not speciﬁed, were purchased from Sigma-
Aldrich Ltd. (Budapest, Hungary). The cytotoxicity tests were carried
out in 96-well microtitre plates, using 5000 cells/well for HeLa and
SiHa and 10,000 cells/well for C33A cells, which were allowed to ad-
here overnight before the drugs were introduced. The original medium
was then removed, 200 μL culture medium containing the compounds
of interest was added and the cells were incubated for 72 h. The tested
extracts and compounds were dissolved in DMSO. The ﬁnal con-
centration of DMSO never exceeded 0.3%, and therefore had no es-
sential eﬀect on the cell growth. Next, the living cells were assayed:
aliquots (20 μL at 5 mg/mL) of the MTT stock solution were pipetted
into each well and reduced by viable cells to an insoluble formazan
product during a further 4 h. The precipitated formazan crystals were
solubilized in 100 μL DMSO by gentle shaking for 60 min. The absor-
bance was determined at 545 nm with an enzyme-linked im-
munosorbent assay reader [6]. In this way the cell growth or drug
toxicity was determined. All in vitro experiments were carried out on
two microplates with ﬁve parallel wells. Based on our previous
antiproliferative activity experiments, cisplatin (IC50 12.43 μM,
7.84 μM, and 3.69 μM, on HeLa, SiHa, and C33A cells, respectively), a
clinically used anticancer agent, was used as the reference substance
[7].
3. Results and discussion
In the course of our study, the phytochemical and pharmacological
investigations of Sideritis montana L. were performed. The dried whole
plant material (2.8 kg) was powdered and extracted with MeOH at
room temperature. After concentration, the extract was dissolved in
50% aqueous MeOH, and solvent–solvent partition was performed with
n-hexane, CHCl3, and ﬁnally with EtOAc. The n-hexane, and CHCl3
fractions were puriﬁed with a combination of diﬀerent chromato-
graphic techniques to yield eight compounds (1–8) (Fig. 1). The
structure elucidation of the compounds was carried out by extensive
spectroscopic analysis, using 1D and 2D NMR (1He1H COSY, HSQC,
HMBC, NOESY) spectroscopy, HRESIMS experiments and comparison
of the spectral data with literature values.
Compound 1 was obtained as an amorphous solid with [α]D26 + 47
(c 0.1, MeOH). Its HRESIMS proved the molecular formula C20H30O2
through the presence of a peak at m/z 285.2217 [M–H2O + H]+ (calcd
for C20H29O, 285.2213) and supported by the hydrogen and carbon
atom counts in the NMR spectra. The 1H NMR spectrum (Table 1)
displayed signals of two ortho-coupled aromatic protons (δH 7.12 d and
7.03 d), and one aromatic proton as a broad singlet (δH 7.33), ﬁve
methyls, three methylenes, four sp3 methines and signals of protons
belonging to two hydroxyl groups. In the JMOD (J-modulated spin-echo
experiment) spectrum, the presence of 20 carbon signals was detected
(Table 1) indicating this compound to be a diterpene. In the 1He1H
COSY spectrum, correlations were observed between protons at δH
3.81 m and 1.04 t and 2.45 brd (H-2/H-1α, H-1β and H-3α), δH 1.55 m
and 1.20 brd and 4.53 dd (H-6β/H-5 and H-7), δH 2.01 dd and 4.53 dd
(H-6α/H-7), δH 7.12 d and 7.03 brd (H-11/H-12), and δH 2.81 sept and
1.16 d (3H) and 1.17 d (3H) (H-15/H3-16 and H3-17) (Fig. 2).
These structural parts and quaternary carbons were connected by
inspection of the long-range HeC correlations observed in the HMBC
spectrum (Fig. 2). The two- and three-bond correlations between H-1,
H-5, H-6, H-11 and H3-20 and the quaternary carbon C-10; H-1, H-5, H-
12, H-14, and H-20 and the quaternary carbon C-9; H-6, H-7, H-11 and
C-8; and ﬁnally H-11, H-14, H-15 and C-13 revealed that the structure
forms an abietane skeleton, frequently occur in diﬀerent Lamiaceae
species. Two of the methyl groups (δH 0.94 s and 0.90 s) were placed at
C-4 on the basis of their HMBC correlations with the quaternary carbon
at δC 34.0 (C-4), and δC 50.5 (C-3) and δC 48.4 (C-5). Another methyl
group was connected to C-10 according to its long-range correlation H3-
20/C-10. The linkage of hydroxy groups to C-2 and C-7 were conﬁrmed
by the chemical shift of the tertiary carbons (δC-2 63.0 and δC-7 69.4).
The NOESY correlations conﬁrmed the stereostructure of compound
1. Overhauser eﬀects were detected between H-1α/H-3α, OH-2/H-1α,
H-2/H3-18 and H-20, H-6α/H-19, OH-7/H-6β, and H-7/H-5 and H-6α.
All of the above evidence conﬁrmed the structure of 1, named as
sideritin A.
Compound 2 was isolated as an amorphous powder with [α]D26− 7
Table 1
NMR data for sideritin A (1).
position 1a 2b
δH (J in Hz) δC, type δH (J in Hz) δC, type
1α 1.04, t (11.8) 47.8, CH2 1.70, m 41.6, CH2
1β 2.45, brd (11.7) 1.79, m
2 3.81, m 63.0, CH 3.85, m 65.1, CH
3α 1.04, t (10.6) 50.5, CH2 1.14, m 51.3, CH2
3β 1.69, brd (10.6) 1.75, m
4 34.0, C 35.2, C
5 1.20, brd (12.7) 48.4, CH 1.56, m 42.6, CH
6α 2.01, dd (12.3, 7.1) 29.3, CH2 2.26, m 29.0, CH2
6β 1.55, m 1.56, m
7 4.53, dd (10.0, 7.1) 69.4, CH 4.71, dd (10.1, 2.8) 67.3, CH
8 138.9, C 146.6, C
9 146.3, C 81.2, C
10 39.3, C 41.0, C
11(α) 7.12, d (8.2) 123.6, CH 2.12, m 23.4, CH2
11β 1.55, m
12 7.03, d (7.7) 124.8, CH 1.99, 2H, m 24.9, CH2
13 145.0, C 79.8, C
14 7.33, brs 125.3, CH 6.47, s 133.7, CH
15 2.81, sept (6.9) 33.1, CH 1.94, m 32.4, CH
16 1.17, 3H, d (7.2) 23.9, CH3 1.01, 3H, d (8.0) 17.4, CH3
17 1.16, 3H, d (7.2) 24.0, CH3 0.99, 3H, d (8.0) 17.5, CH3
18 0.90, 3H, s 22.4, CH3 0.99, 3H, s 24.0, CH3
19 0.94, 3H, s 33.2, CH3 0.95, 3H, s 33.1, CH3
20 1.16, 3H, s 26.1, CH3 1.26, 3H, s 20.0, CH3
2-OH 4.45, d (4.8)
7-OH 5.19, d (7.3)
a Recorded in DMSO-d6 at 500 MHz (1H) and 125 MHz (13C).
b Recorded in CDCl3 at 500 MHz (1H) and 125 MHz (13C).
1 2 3 4
Fig. 1. Structures of compounds 1–4.
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(c 0.2, MeOH). Its HRESIMS provided the molecular formula, C20H32O4,
through the presence of a peak at m/z 359.2198 [M+ Na]+ (calcd for
C20H32O4Na, 359.2193). The 1H NMR spectrum (Table 1) showed sig-
nals characteristic of three tertiary methyls (δH 0.95 s, 0.99 s, and
1.26 s), one isopropyl (δH 1.94 m, 0.99 d and 1.01 d) and one oleﬁnic
proton signal (δH 6.47 s). The JMOD spectrum (Table 1) conﬁrmed the
presence of a trisubstituted double bond (δC 133.7 and 146.6), and also
showed signals attributed to the presence of two quaternary oxygenated
carbons (δC 81.2 and 79.8). Thus, analysis of its 1H and 13C NMR data
suggested that 2 is based on an epi-dioxyabietene structure [8].
According to the correlations observed in the 1He1H COSY spec-
trum the same structural parts could be deduced as in case of 1 with
exception of the aromatic ortho protons which are replaced by the two
correlated methylenes [δH 1.99 m (2H), 2.12 m (1H) and 1.55 m (1H)].
The long-range HeC correlations observed in the HMBC spectrum
(Fig. 2) between H-14 and C-7, C-9, C-12, C-13, and C-15 proved that an
oxygen functionality was present between the C-9 and C-13, which was
identiﬁed as an endoperoxide with regard to the molecular formula.
According to their HMBC correlations methyl groups were placed at C-4
and C-10, and hydroxyl groups at C-2 and C-7, similarly as in case of 1.
The NOESY correlations further conﬁrmed the structure of com-
pound 2. Overhauser eﬀects were detected between H-5/H-6α, H-7 and
H3-19, H3-19/H-6α, and between H3-20/H-1β, H-2, H-6β and H-11β.
The relative stereochemistry at the epoxide for C-9 and C-13 in 2 was
established as α,α by NOESY correlations between H3-20 and H-11β,
similarly as it was observed in case of angustanoic acid B [9]. All these
evidence conﬁrmed the structure of 2, named sideritin B.
Besides the two new diterpenes, sideritin A (1) and B (2), two
known diterpenoids, pomiferin E (3) [10], 9α,13α-epi-dioxyabiet-
8(14)-en-18-ol (4) [8], the lignan paulownin (5) [11], the ﬂavanone 6-
methoxysakuranetin (6) [12], the megastigmane 3-oxo-α-ionol (7)
[13], and 4-allyl-2,6-dimethoxyphenol-glucoside (8) [14] were also
isolated from the methanol extract of S. montana. All of the compounds
were isolated for the ﬁrst time from the plant, however 6-methox-
ysakuranetin (6) was previously reported from other Sideritis species (S.
sventenii) [12]. Since the genus Sideritis is a rich source of ﬂavonoids,
the presence of 6-methoxysakuranetin (6) in the plant was expectedly
[3]. Compounds 1–3 contain hydroxyl group at C-2, which is rare in
nature; such type of components were isolated previously from Salvia
pomifera and Cryptomeria fortune[10,15]. Although great deals of di-
terpenoids were isolated from Sideritis species, until now these com-
pounds have not been detected or isolated from S. montana[16]. Four
compounds were obtained earlier from other Lamiaceae species, 3-oxo-
alfa-ionol (7) and 4-allyl-2,6-dimethoxyphenol-glucoside (8) were iso-
lated from Glechoma longituba[17,18], pomiferin E (3) was identiﬁed
from S. pomifera[10] and compound 4 from Hyptis suaveolens[19]. The
13C NMR data of 3 was published here for the ﬁrst time (see Section
2.3.3).
Diterpenes can be considered as chemotaxonomic markers for plants
belonging to the genus Sideritis. S. montana was categorized into the
Hesiodia section. Plants belonging to this section produces triterpenes or
sterols, but among their secondary metabolites diterpenoids were not
found [20]. The isolation of diterpenoids with unusual 2-hydroxy
substitution from S. montana conﬁrms its close relationship with the
section Empedoclea[3,20].
Previously, abietane-type diterpenes were tested for their anti-
tumor-promoting activities, by measuring the inhibitory activity of the
compounds on EBV-EA (Epstein-Barr virus early antigen) activation
induced by TPA (12-O-tetradecanoylphorbol-13-acetate) and potent or
moderate inhibitory eﬀects were observed [21,22]. In our study, the
antiproliferative properties of the isolated compounds were determined
on three human cancer (HeLa, SiHa and C33A) cell lines, at 10 and
30 μM concentrations. In the performed assay, in vitro cell growth in-
hibitory eﬀects were measured by the use of MTT assay. Among the
isolated compounds, considerable inhibitory activities (above 40%
growth inhibition) were measured for pomiferin E (3) on HeLa cell line
(inhibition (%) ± SEM: 46.93 ± 2.35) and for 6-methoxysakuranetin
(6) on C33A cells (inhibition (%) ± SEM: 51.52 ± 2.45), at 30 μM
concentration. Moderate inhibitory eﬀects (20–40% growth inhibition)
were detected for sideritin A (1) on HeLa (28.34 ± 2.46%) and SIHA
cells (26.87 ± 0.88%), pomiferin E (3) on SIHA cells
(24.49 ± 2.22%) and compound 6 on HeLa (39.70 ± 2.64%) and
SIHA (35.49 ± 2.49%) cells, at 30 μM concentration. Other com-
pounds proved to be inactive on the tested cell lines.
Previously, 9α,13α-epi-dioxyabiet-8(14)-en-18-ol (4) was tested
against A549 (human lung carcinoma), H-116 (human colon carci-
noma), PSN1 (human pancreatic adenocarcinoma), T98G (human
caucasian gioblastoma), and SKBR3 (human breast carcinoma) cell
lines, but it had no inhibitory eﬀect on them [8]. In our study, this
compound was also proved to be inactive on the tested cell lines. The
antiproliferative property of the other isolated compounds was not
studied before.
In conclusion, our results allowed the identiﬁcation of four abietane
diterpenes (1–4) substituted with hydroxyl and endoperoxide groups,
two of them [sideritins A (1) and B (2)] are new natural products.
Moreover, a lignan (5), a ﬂavanone (6) a methoxystigmane (7), and a
phenol-glucoside (8) were also isolated from the plant. Finally, this was
the ﬁrst time when the antiproliferative properties of the above-
mentioned compounds were established and remarkable activities were
detected for pomiferin E (3) and 6-methoxysakuranetin (6).
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